Flatiron Health

Hear from Flatiron Health's Head of Research Oncology Ivy Altomare MD on our impactful research being presented this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. #ASCO24 Join Ivy and the rest of the team at booth #11123 to see our full list of research and learn how our evidence solutions can accelerate your next oncology breakthrough. Learn more and schedule time with the team: http://spkl.io/60424f1A6

During #NationalCancerResearchMonth this May, we're spotlighting a recent collaborative study published in Journal of Clinical Oncology with Yale Cancer Center. The study unveils a concerning link between aggressive cancer treatment at the end of life (EOL) and adverse outcomes, such as increased emergency visits and hospitalizations. Despite efforts to address this issue, there's been no significant improvement. By analyzing a substantial real-world dataset, researchers identified factors associated with high rates of systemic therapy at EOL for advanced cancer patients. This insight can inform collaborative efforts among researchers, healthcare providers, and policymakers to elevate end-of-life care, enhance patient experiences, and ensure a more peaceful death. Learn more about why this matters: http://spkl.io/60414f1fh

As we celebrate #NationalCancerResearchMonth this May, we shine light on Flatiron Health's role in securing FDA approval for a new dosing regimen of ERBITUX. This biweekly option, supported by Flatiron RWD, offers significant benefits to patients battling metastatic colorectal cancer or squamous cell carcinoma of the head and neck. The approval highlights the critical role of RWD in regulatory decisions and addressing post-approval evidence gaps. Learn more about how RWD can support post-approval benefits from industry experts: https://lnkd.in/euHHzi5K

ANNOUNCED TODAY: A total of nine abstracts led by Flatiron Health accepted for poster presentation and online publication at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights: - A study employing machine-learning models across a nationwide cohort to explore practice patterns in the face of chemotherapy shortages - A study exploring the role of biomarkers in guiding treatment for metastatic breast cancer (mBC) - A study examining how structural racism and SDoH contribute to inequities in endometrial cancer care Learn more about our research ⤵️ http://spkl.io/604644SIG

Using systemic anti-cancer therapy (SACT) near end-of-life (EOL) is linked to negative outcomes, including increased hospitalization and costs. Despite recommendations to reduce chemotherapy within 14 days of death, national SACT rates in this period remain unchanged. Critics argue that EOL metrics might miss patients benefiting from aggressive treatment. In this #newresearch published in JAMA Oncology, researchers from Yale Cancer Center, MD Anderson Cancer Center, and Flatiron Health explore if “aggressive” SACT use near EOL improved outcomes in advanced/metastatic cancer patients. This research challenges common EOL oncology practices and emphasizes the need to understand economic factors shaping treatment decision in the evolving landscape of EOL oncology care. Visit our website to learn more: https://lnkd.in/e6ftweKk

Health data has the potential to transform healthcare systems across the globe, driving innovative research and improving care for patients. Flatiron UK’s Adam Manhi recently shared his thoughts on how the UK can unlock innovation using high-quality health data, providing specific recommendations to accelerate data utilisation. Read more now: http://spkl.io/6043443qT

We're excited to continue improving the experience for OncoEMR® users through our collaboration with Canopy ⬇ This collaboration not only supports our provider network, but has the potential to improve patient care and outcomes—driving progress towards our mission to improve and extend lives by learning from the experience of every person with cancer.

What happens to patient data when it is shared with Flatiron UK? Hear more from one of the members of our Patient Voices Panel, Linda Galbraith, in conversation with one of our software engineers— ‘I've seen first hand the benefits of the data sharing model that Flatiron uses. By building partnerships with NHS Trusts, Flatiron receives anonymised patient data, which they structure and standardise to help identify trends that could improve patient care and outcomes. Despite my fears, I realised that all data being used by Flatiron was being protected, anonymised, and analysed in a trusted, secure environment by staff who are experienced and understand the importance of handling the data securely.” https://lnkd.in/eQkXVmZp

In recognition of #NationalCancerResearchMonth this May, we're highlighting a recent study published in NEJM Evidence. Despite significant investments, certain demographics are notably absent from clinical trials, limiting progress for underserved populations. Our research, utilizing #RWD, examines how expanding eligibility criteria in cancer trials could boost representation for marginalized groups, offering practical insights for inclusive trial design. These findings contribute to more equitable and effective cancer research. Hear from Maneet Kaur, PhD, MPH, Senior Quantitative Scientist about the study's inspiration and explore the full publication: http://spkl.io/604444EO8

Post-marketing requirements and commitment studies (PMR/PMCs) associated with drug approval can take years to complete and cost millions of dollars. A new analysis by Flatiron shows how applying #RWE can alleviate the burden and maximize the impact of PMRs/PMCs, assessing which study types are best suited for application of RWE. Read more now: https://lnkd.in/eC-ZxFR9